Uploaded July 2024 | Updated September 2026, 2 weeks ago
#Brachytherapy For #ProstateCancer | Steven Kurtzman, MD & Ankit Agarwal, MD #pcri
youtu.be/GZTK6IcGI-w?feature=shared
Donate to PCRI: pcri.org/donate
For more information, visit pcri.org
0:44 Which is better low-dose-rate or high-dose-rate seed therapy?
1:57 Which type of brachytherapy is more common?
3:35 Does high-dose-rate therapy have a higher incidence of side effects?
4:10 Will brachytherapy seeds affect one's ability to get an MRI or CT scan?
4:40 Are there advantages of one isotope over another?
5:56 Is brachytherapy a better solution for preserving the sphincter or urethra?
7:40 Does Prostox work for brachytherapy?
8:03 What about loss of orgasms without ED?
9:09 With brachytherapy is 12 months of ADT sufficient with a Gleason 8 small lesion?
10:25 Which side effects are most common with brachytherapy?
11:01 Is brachytherapy usually covered by most insurances?
11:10 Is brachytherapy no longer an option if there's too much cancer present?
12:42 Alex's conclusions
14:57 If you need more help
Don't know your stage? Take the quiz: visit prostatecancerstaging.org
To learn more about prostate cancer, visit pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
#Brachytherapy For #ProstateCancer | Steven Kurtzman, MD & Ankit Agarwal, MD #pcri
youtu.be/GZTK6IcGI-w?feature=shared
Donate to PCRI: pcri.org/donate
For more information, visit pcri.org
0:44 Which is better low-dose-rate or high-dose-rate seed therapy?
1:57 Which type of brachytherapy is more common?
3:35 Does high-dose-rate therapy have a higher incidence of side effects?
4:10 Will brachytherapy seeds affect one's ability to get an MRI or CT scan?
4:40 Are there advantages of one isotope over another?
5:56 Is brachytherapy a better solution for preserving the sphincter or urethra?
7:40 Does Prostox work for brachytherapy?
8:03 What about loss of orgasms without ED?
9:09 With brachytherapy is 12 months of ADT sufficient with a Gleason 8 small lesion?
10:25 Which side effects are most common with brachytherapy?
11:01 Is brachytherapy usually covered by most insurances?
11:10 Is brachytherapy no longer an option if there's too much cancer present?
12:42 Alex's conclusions
14:57 If you need more help
Don't know your stage? Take the quiz: visit prostatecancerstaging.org
To learn more about prostate cancer, visit pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
